The Journal of Allergy and Clinical Immunology
Volume 120, Issue 5 , Pages 1036-1042 , November 2007

Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma controL study

  • Søren E. Pedersen, MD, DMSc

      Affiliations

    • Department of Pediatrics, University of Southern Denmark, Pediatric Research Unit, Kolding Hospital, Kolding, Denmark
    • Corresponding Author InformationReprint requests: Søren E. Pedersen, MD, DMSc, University of Southern Denmark, Department of Pediatrics, Pediatric Research Unit, Kolding Hospital, Kolding DK 6000, Denmark.
    • ,
  • Eric D. Bateman, MD

      Affiliations

    • Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa
    • ,
  • Jean Bousquet, MD

      Affiliations

    • Hôpital Arnaud de Villeneuve, Montpellier, France
    • ,
  • William W. Busse, MD

      Affiliations

    • Department of Medicine, University of Wisconsin–Madison Medical School, Madison, Wis
    • ,
  • Sally Yoxall, MSc

      Affiliations

    • GlaxoSmithKline, Greenford, Middlesex, United Kingdom
    • ,
  • Tim J. Clark, MD

      Affiliations

    • National Heart and Lung Institute, Imperial College, London, United Kingdom
    • ,
  • Gaining Optimal Asthma controL Steering Committee and Investigators

Received 15 February 2007 ,Revised 5 July 2007 ,Accepted 12 July 2007.

References 

  1. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma controL study. Am J Respir Crit Care Med. 2004;170:836–844
  2. Global Initiative for Asthma . Global Initiative for Asthma (GINA) Pocket guide for asthma management and prevention. Bethesda (MD): National Institutes of Health, National Heart, Lung, and Blood Institute; 1998;Publication no. 95-3659B
  3. National Institutes of Health . National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma: expert panel report 2. Bethesda (MD): National Institutes of Health, National Heart, Lung and Blood Institute; 1997;Publication no. 97-4051
  4. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med. 2003;168:1308–1311
  5. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax. 2002;57:226–230
  6. Tomlinson JE, McMahon AD, Chaudhuri R, Thompson JM, Wood SF, Thomson NC. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax. 2005;60:282–287
  7. Jang AS, Lee JH, Park SW, Lee YM, Uh ST, Kim YH, et al. Factors influencing the responsiveness to inhaled glucocorticoids of patients with moderate-to-severe asthma. Chest. 2005;128:1140–1145
  8. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley; 2000;
  9. CPMP/EWP/2863/99 Points to consider on adjustment for baseline covariates. European Agency for the Evaluation of Medicinal Products. Available at: http://www.emea.europa.eu/pdfs/human/ewp/286399en.pdf.Accessed June 1, 2007.
  10. Lazarus SC, Chinchilli VM, Rollings NJ, Boushey HA, Cherniack R, Craig TJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med. 2007;175:783–790
  11. Schatz M, Zeiger RS, Vollmer WM, Mosen D, Cook EF. Determinants of future long-term asthma control. J Allergy Clin Immunol. 2006;118:1048–1053
  12. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med. 1998;339:1194–1200
  13. Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol. 2006;117:522–543
  14. Thomson NC, Spears M. The influence of smoking on the treatment response in patients with asthma. Curr Opin Allergy Clin Immunol. 2005;5:57–63
  15. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA). Available at: http://www.ginasthma.org/Guidelineitem.asp??l1=2&l2=1&intId=60. Accessed January 9, 2007.
  16. Leynaert B, Bousquet J, Henry C, Liard R, Neukirch F. Is bronchial hyperresponsiveness more frequent in women than in men? A population-based study. Am J Respir Crit Care Med. 1997;156:1413–1420
  17. Trigg CJ, Bennett JB, Tooley M, Sibbald B, D'Souza MF, Davies RJ. A general practice based survey of bronchial hyperresponsiveness and its relation to symptoms, sex, age, atopy, and smoking. Thorax. 1990;45:866–872
  18. Britton J, Pavord I, Richards K, Knox A, Wisniewski A, Wahedna I, et al. Factors influencing the occurrence of airway hyperreactivity in the general population: the importance of atopy and airway calibre. Eur Respir J. 1994;7:881–887
  19. Bottema RW, Reijmerink NE, Koppelman GH, Kerkhof M, Postma DS. Phenotype definition, age, and gender in the genetics of asthma and atopy. Immunol Allergy Clin North Am. 2005;25:621–639
  20. Dijkstra A, Howard TD, Vonk JM, Ampleford EJ, Lange LA, Bleecker ER, et al. Estrogen receptor 1 polymorphisms are associated with airway hyperresponsiveness and lung function decline, particularly in female subjects with asthma. J Allergy Clin Immunol. 2006;117:604–611
  21. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47:76–83

 The funding for the original Gaining Optimal Asthma controL study (GSK study no. CCC3456788) from which these data were derived was from GlaxoSmithKline R&D.

 Disclosure of potential conflict of interest: S. E. Pedersen has consulting arrangements with GlaxoSmithKline, Nycomed, and Merck and has received grant support from GlaxoSmithKline, Nycomed, and AstraZeneca. E. D. Bateman has consulting arrangements with GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Altana, Kyowa Hakko, Hoffman La Roche, Almirall, and Merck and is on the speakers' bureau for GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, and Altana. J. Bousquet has consulting arrangements with and has received grant support from GlaxoSmithKline. W. W. Busse has consulting arrangements with Genentech/Novartis, Isis, GlaxoSmithKline, Altana, Wyeth, Pfizer, Dynavax, and Centocor; has received grant support from Novartis, Wyeth, Dynavax, and Centocor; and is on the speakers' bureau for GlaxoSmithKline, Novartis, Merck, and AstraZeneca. S. Yoxall is employed by GlaxoSmithKline. T. J. Clark has consulting arrangements with GlaxoSmithKline.

PII: S0091-6749(07)01387-5

doi: 10.1016/j.jaci.2007.07.016

The Journal of Allergy and Clinical Immunology
Volume 120, Issue 5 , Pages 1036-1042 , November 2007

Article Tools

* Image Usage & Resolution